Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$4.81 USD
-0.18 (-3.61%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $4.80 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Aldeyra Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ALDX 4.81 -0.18(-3.61%)
Will ALDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALDX
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
Other News for ALDX
ALDX Gains Orphan Status in Europe for Vision Loss Treatment | ALDX Stock News
Aldeyra receives orphan designation for ADX-2191 from EMA
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ...
Commit To Buy Aldeyra Therapeutics At $2.50, Earn 28.4% Annualized Using Options
Aldeyra (ALDX) Resubmits Reproxalap NDA to FDA